Can a simple pill prevent deadly clots in lung cancer patients?
NCT ID NCT07160686
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether the blood thinner apixaban can prevent dangerous blood clots in people with lung cancer who are receiving chemotherapy or similar treatments. About 1,456 participants will take either apixaban or a placebo twice a day for six months. The goal is to see if apixaban reduces the number of clots without causing serious bleeding.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- apixaban (a blood thinner)
- What this could lead to
- If it works, this could provide a safe way to prevent blood clots in lung cancer patients, reducing hospitalizations and deaths from clots.
- What could go wrong
- This is a large phase 3 trial, but blood thinners carry a risk of bleeding. The benefit may not outweigh the risk for all patients, and results may not apply to other cancers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Birmingham
Birmingham, B15 2TT, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Your Tumor's DNA might predict immunotherapy success
- Can a new PET tracer light up hidden cancers?
- Fellow veterans may hold the key to earlier lung cancer detection